MiMedx Receives 2015 Innovative Technology Award from Novation

MARIETTA, Ga., May 8, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Novation has recognized MiMedx as a recipient of Novation's Innovative Technology award for 2015. MiMedx also announced that it has entered into a national agreement with Novation.

Novation is the country's leading health care services company for the more than 100,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association, and Provista LLC.

Parker H. Petit, MiMedx Chairman and CEO, said, "We are extremely honored to announce that MiMedx has received an Innovative Technology award from Novation. We are also very pleased to provide our EpiFix® and AmnioFix® allografts to the members and affiliate organizations served by Novation."

The national contract with Novation will be effective on June 1, 2015, and the more than 100,000 members and affiliates they represent will be offered MiMedx allografts through Novation. "We have made substantial investments and dedicated significant resources in the development of our proprietary technology, the production of our Compendium of clinical and scientific study results, and the attainment of rapid coverage acceptance among health plans. MiMedx was awarded the Innovative Technology award following a review by more than 200 attendees from hospitals around the United States who serve on a Novation council or task force and participated in the Expo," stated Petit.   

"This new designation will identify MiMedx as an awarded Innovative Technology product within Novation's online contract catalog. This heightened visibility will encourage further consideration by members accessing this agreement," added Petit.

Bill Taylor, MiMedx President and COO, commented, "We are continually increasing the base of patients who have access to and can benefit from our clinically effective and cost effective allografts. This major contract will now offer hundreds of thousands of patients our proprietary technology through the Novation portfolio."

About Novation

Novation is the nation's leading health care services company, focused on revolutionizing operational performance for more than 100,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association and Provista LLC. Novation's progressive approach to cost performance, data and intelligence, and integrated advisory solutions helps health care providers envision and advance new models of cost-effective, high-quality care. Headquartered in Irving, Texas, Novation is committed to the highest standards of ethical behavior and twice has been honored with the Ethisphere Institute's coveted Ethics Inside® Certification, and has been named four years consecutively to Ethisphere's World's Most Ethical Companies list.

About MiMedx

MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 400,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. 

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, that the Innovative Technology Award will give the Company heightened visibility with Novation members and this heightened visibility will encourage further consideration and/or use by members, that the Company will continue to increase the base of patients who have access to the Company's products, and that the patients who have access to the products can benefit from them.  These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Innovative Technology Award does not give the Company heightened visibility or that it does give heightened visibility but does not result in Novation members increasing their consideration and/or use of the Company's products, that the Company does not continue to increase the base of patients who have access to its products, that the patients who have access to the Company's products do not benefit from them in the way that is expected or at all, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2014 and its most recent Form 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

SOURCE MiMedx Group, Inc.

Related Links

http://www.mimedx.com